Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "net-profit"

576 News Found

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
News | February 05, 2022

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore

Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021

IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
News | February 05, 2022

IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore

IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore
News | February 05, 2022

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore

Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021

Lupin Q3FY22 PAT at Rs 545.52 cr.
News | February 04, 2022

Lupin Q3FY22 PAT at Rs 545.52 cr.

Lupin has reported consolidated financial results for the period ended December 31, 2021

Pfizer Q3FY22 PAT at Rs 143.91 crore
News | February 04, 2022

Pfizer Q3FY22 PAT at Rs 143.91 crore

The company has reported standalone financial results for the period ended December 31, 2021.

Caplin Point Q3FY22 PAT at Rs 74.95 cr.
News | February 03, 2022

Caplin Point Q3FY22 PAT at Rs 74.95 cr.

Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
News | January 31, 2022

Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.

Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News | January 28, 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021

Torrent Pharmaceuticals consolidated PAT at Rs 249 cr
News | January 26, 2022

Torrent Pharmaceuticals consolidated PAT at Rs 249 cr

Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
News | January 21, 2022

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021

Latest Stories

Pawan Varshney elevated to Director of Finance – South Asia at Cepheid

Nitin Wadhwa joins Sebia as General Manager to lead India growth

PFCD panel flags insurance gaps limiting access to robotic joint replacement in India

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi
Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India
Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India
Kavinder Beniwal Chief Operational Officer, Motorica India
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics

Packaging